| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_54ae5e452ed609179e635c91ad116e6a |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-531
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2320-51
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2320-53
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-3231
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-317
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-315
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-321
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-322
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-346 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-111
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-113 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-113 |
| filingDate |
2016-10-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_366ee3ebe4409d7b51e527c6a4fcabe8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_775aada4a85008b341977094da597b2e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_05f63b30be6bbd5e1cc7f004d7425558
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a5c66ba575bc5a0fb64b1601e9505add
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_089780a54381faa2b1897e9a5fc508b8 |
| publicationDate |
2017-02-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2017044536-A1 |
| titleOfInvention |
Crispr-based compositions and methods of use |
| abstract |
This invention pertains to modified compositions for use in CRISPR systems, and their methods of use. In particular, length-modified and chemically-modified forms of crRNA and tracrRNA are described for use as a reconstituted guide RNA for interaction with Cas9 of CRISPR systems. The resultant length-modified and chemically-modified forms of crRNA and tracrRNA are economical to produce and can be tailored to have unique properties relevant to their biochemical and biological activity in the context of the CRISPR Cas9 endonuclease system. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11279928-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2018187186-A1 |
| priorityDate |
2014-12-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |